• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

News Update: Active monitoring works for newborns with mild hip dysplasia

Article

Employing active sonographic surveillance in newborns with mild hip dysplasia yields results similar to those achieved with immediate splinting treatment, according to a new study.

Employing active sonographic surveillance in newborns with mild hip dysplasia yields results similar to those achieved with immediate splinting treatment, according to a new study.

In a randomized, blinded, controlled study published online ahead of print in Pediatrics, researchers assigned 128 newborns with mild hip dysplasia in 1 or both hips to either 6 weeks of immediate abduction splinting treatment with sonographic follow-up (n=64) or active sonographic surveillance alone (n=64). Patients were assessed at 6 weeks, 3 months, 6 months, and 1 year, and treatment was either continued or discontinued (splinting group) or initiated or not initiated (active surveillance group) based on the sonographic inclination angle. At 1.5 months of age, 47% of patients in the active surveillance group received treatment. In both groups, the mean treatment duration was 12 weeks. At 1 year of age, the mean inclination angle was 24.2° in both groups (P=.82). A total of 38 patients treated with splinting and 40 patients treated with active surveillance had radiologically normal hips at 1 year of age.

Considering the reported prevalence of 1.3% for mild hip dysplasia, these results suggest that a strategy of active surveillance rather than immediate treatment could reduce the overall treatment rate by 0.6%.

Related Videos
Donna Hallas, PhD, CPNP, PPCNP-BC, PMHS, FAANP, FAAN
Scott Ceresnak, MD
Scott Ceresnak, MD
Importance of maternal influenza vaccination recommendations
Reducing HIV reservoirs in neonates with very early antiretroviral therapy | Deborah Persaud, MD
Samantha Olson, MPH
Deborah Persaud, MD
Ari Brown, MD, FAAP | Pediatrician and CEO of 411 Pediatrics; author, baby411 book series; chief medical advisor, Kabrita USA.
© 2024 MJH Life Sciences

All rights reserved.